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Gastro-Oesophageal 
Reflux Disease – GORD
Symptoms of gastro-oesophageal reflux disease (GORD) have a 
substantial impact on patients’ everyday lives.  In the majority of 
situations patients can be managed empirically with over-the-counter 
preparations, however some patients presenting with alarm signs will 
require urgent referral for endoscopic studies. 
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Introduction
GORD is a collective term embracing 
all diseases caused by gastro-oesophageal 
reflux.1  Gastro-oesophageal reflux is a 
disorder in which the oesophageal mucosa 
is damaged by the reflux of gastric or 
intestinal contents into the oesophagus and 
results in patient complaints of heartburn 
and other symptoms such as ‘burping up’ 
stomach contents or  the taste of bitter 
contents in the mouth.2 Although the 
classical symptom is “heartburn”, at times 
it presents itself as pain in the centre of the 
chest, which might mimic cardiac angina2 
or asthma.1  Twenty-five percent of adults 
experience heartburn at least once a month 
and most of these are treated empirically.3 
The prevalence and incidence of GORD has 
doubled in a period of ten years, and this 
increase is being linked to dietary and 
lifestyle changes.
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Pathophysiology	of	GORD
The development of GORD is associated 
with a disruption of the balance between 
defensive mechanisms (lower oesophagus 
closure and oesophageal peristalsis) and 
aggressive factors (e.g. acid, pepsin, bile 
salts).2  
There are three pathophysiologic 
mechanisms, which predispose a patient to 
reflux:
1. a spontaneous transient or sustained 
relaxation of the lower oesophageal 
sphincter (LOS);
2. a low resting lower oesophageal pressure;
3. increased gastric pressure.2
GORD is associated with long-term 
morbidity and mortality. Complications 
of GORD are oesophagitis which if severe 
can cause erosive changes, oesophageal 
ulcers, strictures, haemorrhage, perforation, 
aspiration and the development of Barrett’s 
oesophagus.  Barrett’s oesophagus 
predisposes the patient to the development 
of oesophageal cancer.2
Treatment
The primary aim of treatment is 
complete clinical remission and prevention 
of long-term complications.   Pharmacists 
are in an ideal position to monitor, advise 
and refer patients accordingly. 
Lifestyle	changes
Some foods are known to irritate the 
gastric mucosa such as spicy food and citric 
juices; others may stimulate acid secretion 
as cola and beer, whereas some are known 
to lower oesophageal sphincter pressure 
such as foods with a high-fat content.2,6  
Although epidemiological studies fail to 
show any association between food and 
GORD, some patients may benefit from 
avoiding such foods. Some drug therapy 
such as alcohol, beta-adrenoceptor agonists, 
diazepam, progesterone, theophylline and 
verapamil, can also exacerbate GORD.2
Obesity and tight clothes may 
exacerbate reflux by continuously increasing 
the gastro-oesophageal pressure gradient.2 
Additional advice which may benefit 
patients with reflux symptoms include, 
smoking cessation, avoiding meals 2-3 
hours before lying down and avoiding 
bending down.2  
Drug	therapy
When recommending drug therapy, 
pharmacists need to keep in mind patient 
co-morbidities especially in the elderly and 
also interactions with other medications.
Antacids can provide relief of mild 
to moderate symptoms associated with 
GORD because of their ability to neutralise 
gastric acid and to increase LOS pressure.  
However antacids have no role in promoting 
healing of oesophagitis and consequently 
are only useful in providing symptomatic 
relief.  Antacids should be used only as 
an adjunct.2  Calcium containing antacids 
should be avoided as they can induce 
rebound acid section.7
H2-Receptor antagonists (H2RAs) 
can be effective for management of mild 
to moderate GORD when used in full 
doses.  Healing rates in patients with 
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mild pre-treatment oesophageal reflux are 
significantly better than in those with 
moderate or severe pre-treatment disease.  
H2-antagonists should be administered in 
daily divided doses because gastric acid 
suppression or neutralization throughout 
the day is important in the treatment of 
reflux disease.2  
Proton Pump Inhibitors	(PPIs)	inhibit 
gastric acid secretion for a sustained period 
of time and are highly effective in the 
treatment of GORD.2  In a direct comparison 
PPIs were found to be more effective than 
H2RAs in relieving heartburn in patients 
with GORD.3  The disadvantages of PPIs are 
their relatively slow onset of action, limited 
activity to the post-prandial period and 
limited efficacy in reducing nocturnal acid 
secretion.8  
Sucralfate appears to be effective in 
resolving mild cases of oesophagitis but 
it appears less effective in management 
of severe disease.  This drug should be 
administered four times daily preferably as a 
suspension because the drug needs to be in 
direct contact with the damaged mucosa.2,7  
Metoclopramide stimulates the motility 
of the upper gastrointestinal tract without 
affecting gastric acid secretion. When 
administered as 10mg four times a day, 30-
60 minutes before meals and at bedtimes, 
it increases gastric peristalsis, which 
leads to accelerated gastric emptying thus 
decreasing the intestinal transit. Because 
of its adverse effect profile and the general 
lack of gastrointestinal motility dysfunction 
in adult patients with GORD, its usefulness 
is significantly limited.2,7
Nocturnal	reflux
Patients complaining of night-time 
GORD should be given particular attention.9  
Nocturnal reflux designates a greater risk 
of erosive oesophagitis and additionally 
these patients have a reduced quality of 
life as GORD interferes with sleep and 
consequentially next-day mental and 
physical functioning.10  These patients 
usually benefit from:9
• elevating the head of the bed;
• adjusting sleeping position;
• full dose PPI at night;
• low dose PPI on a twice daily regimen; or
• full dose PPI in the morning plus a short 
intermittent course of an H2RA at night.
When	to	refer	patients
Patients should always be referred for 
endoscopy studies if they show any of the 
following
ALARM signs:6,11,12
• GI bleeding (such as haematemesis, 
malaena) 
• Dysphagia
• Unintentional weight loss
• Abdominal swelling
• Epigastric mass
• Persisting vomiting
Gastro-oesophageal	reflux	in	infants
Gastro-oesophageal reflux and GORD 
are common in the first months of life and 
is often linked to the immaturity of the 
oesophagus and stomach and the higher 
liquid intake of infants.13  Some also 
claim that genetic factors are involved.13 
Symptoms include regurge and vomiting.  
Simple measures like using thickened 
formulas are useful in reducing regurgitation 
but occasionally treatment with alginates 
and PPIs is necessary.1  The alginate 
suspension is licensed only for children 
over the age of two but the alginate oral 
powder can be used in neonates unless they 
are preterm.7  The only PPI licensed for use 
in children (over the age of one year) is 
omeprazole, which is conveniently available 
in dispersible tablets.1  Infants with 
suspected reflux should always be referred.
Pregnancy-associated	reflux	
It is estimated that 30-0% of all 
pregnant women experience dyspepsia 
which is most commonly due to gastro-
oesophageal reflux, caused by transient 
relaxation of the lower oesophageal 
sphincter. Altered oesophageal motility 
and increased abdominal pressure may also 
play a role in the pathogenesis of reflux.  
Symptoms can occur at any time during 
pregnancy but are more common and severe 
during the last trimester.16 
First-line	treatment	-	Lifestyle	advice:16
• Avoid precipitating factors as coffee, 
fatty foods, alcohol, smoking, spicy 
foods, citrus products;
• Eat smaller meals;
• Do not eat within 3 hours of bedtime;
• Wear looser clothes;
• Raise head of bed when sleeping.
Second-line	treatment	–	antacids:
When choosing an antacid for a pregnant 
patient one must bear in mind that not all 
antacid preparations are licensed for use in 
pregnancy.  Additionally one must remember 
to choose a low sodium product especially 
in patients with gestational hypertension 
and pre-eclampsia.16  Patients should also 
be advised to leave a minimum of 2 hours 
between antacids and iron supplements.7,16  
Licensed antacids include:
•	 Co-magaldrox (magnesium hydroxide 
19mg & dried aluminium hydroxide 
220mg/ml) low sodium.  Dose: 10-20ml, 
20-60 minutes after food and at bed-time, 
or when required.  Manufacturer advises to 
avoid in the first trimester, as there is no 
clinical data on exposed pregnancies.17
•	 Sodium	alginate	00mg/ml(sugar-free) 
Dose: -10ml, after meals and at bed-time 
when required.  Studies have failed to 
show any significant adverse effects of 
this product on the course of pregnancy or 
on the health of the foetus.18 
 
Third-line	treatment
None of the H2-receptor antagonists 
currently on the market are licensed for 
use in pregnancy. Cimetidine showed 
inhibition of testicular descend and genital 
differentiation in pregnant rodents.19 
Ranitidine crosses the placenta and should 
only be used during pregnancy if considered 
essential. Surveillance studies do not suggest 
that ranitidine presents a major teratogenic 
risk when used in recommended doses but 
regardless of this it is still unlicensed in 
pregnancy.20  
Omeprazole is now licensed in pregnancy 
as there is no evidence of adverse effects on 
pregnancy or on the health of the foetus at 
a dose of 20mg once daily.21 Other proton 
pump inhibitors are not recommended, as 
there is insufficient evidence to recommend 
the use of these drugs in pregnancy.16  
Patients should be referred if:
• symptoms do not respond adequately to 
lifestyle measures and over-the-counter 
preparations;
• they are not eating sufficiently or are 
progressively loosing weight;
• they have signs and symptoms of GI 
bleeding, dysphagia or persisting 
vomiting.16
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Conclusion
Despite major advances in the 
understanding of GORD, management 
remains a challenge, as some patient needs 
are still unmet.8,22  New products, which 
have a faster onset of action, complete 
acid inhibition together with improved 
duration of efficacy, are being developed.  
These include potassium competitive ATPase 
blockers (PCABs), histamine H3 agonists and 
gastrin antagonists.8
Practice	points
• Gastroesophageal reflux is a lifelong disease that requires lifestyle modifications as 
well as medical intervention.
• Self-treatment with antacids or alginate therapy may be appropriate for immediate 
relief of occasional heartburn, however their duration of action is less than two hours.
• Magnesium containing antacids should not be used in patients with renal failure.
• H2RAs have a delay in onset of at least 30 minutes however they provide heartburn 
relief for up to 8 hours. Recommend to take preparations before meals known to cause 
heartburn.
• Proton pump inhibitors are increasingly being used first line as they provide superior 
efficacy and once-daily dosing regimen.
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